ViTi, Inc. was formed to improve T cell diagnostic technology based, in part, discovered at Oregon Health and Science University. The company is currently focused on diagnostics for infectious diseases, including tuberculosis. ViTi, Inc.’s participation in the diagnostic value chain falls mainly in the discovery and development of antigens and methods that can increase the effectiveness of current T cell diagnostic platforms. ViTi Inc. uses a mix of in-licensing and in-house research to fuel its current and future development programs. Founded by Deborah Lewinsohn, MD and David Lewinsohn, MD, PhD in 2009, ViTi, Inc. is the corporate embodiment of decades of medical and research experience involving infectious diseases.